Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials

Journal of Clinical Lipidology

Volumn 8, Issue 4, 2014, Pages 441-447

  Sniderman, Allan D ^a   Sloand, James A ^b   Li, Philip K T ^c   Story, Ken ^b   Bargman, Joanne M ^d  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Diabetes; Lipid metabolism; Lipoproteins; Low glucose dialysis; Peritoneal dialysis

Indexed keywords

AMINO ACID; ANTILIPEMIC AGENT; APOLIPOPROTEIN; GLUCOSE; ICODEXTRIN; LIPID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERITONEAL DIALYSIS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; AGED; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DYSLIPIDEMIAS; FOLLOW UP; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; APOLIPOPROTEINS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES;

EID: 84905994143     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.03.007     Document Type: Article

References (32)

1. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl. 2006;103:S3-11.
2. Johnson DW, Dent H, Hawley CM, et al. Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clin J Am Soc Nephrol. 2009;4:1620-1628.
3. USRDS. 2008 Annual Data Report. Available at: http://www.usrds. org/atlas08.aspx. Accessed May 10, 2013.
4. Prichard S, Cianflone K, Sniderman A. The role of the liver in the pathogenesis of hyperlipidemia in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis. Perit Dial Int. 1996;16(Suppl 1):S207-S210.
5. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447-459.
6. Holewijn S, Sniderman AD, Den Heijer M, Swinkels DW, Stalenhoef AF, De Graaf J. Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: apoB dyslipoproteinemias in a Dutch population-based study. Eur J Clin Invest. 2011;41:423-433.
7. Holmes CJ. Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution. J Diabetes Sci Technol. 2009;3:1472-1480.
8. Burkart J. Metabolic consequences of peritoneal dialysis. Semin Dial. 2004;17:498-504.
9. Sniderman AD, Zhang Z, Cianflone K. Divergent responses of the liver to increased delivery of glucose or fatty acids: implications for the pathogenesis of type IV hyperlipoproteinemia. Atherosclerosis. 1998;137:291-301.
10. Sniderman AD, Cianflone K, Arner P, Summers L, Frayn KN. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol. 1998;18:147-151.
11. Sniderman A, de Graaf J, Couture P, Williams K, Kiss RS, Watts GF. Regulation of plasma LDL: the apoB paradigm. Clin Sci (Lond). 2009; 118:333-339.
12. Sniderman AD, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb. 1993;13:629-636.
13. Sniderman AD,Williams K, Contois JH, et al. A meta-analysis of lowdensity lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337-345.
14. Paniagua R, Ventura MD, Avila-Diaz M, et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int. 2009;29:422-432.
15. Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif. 2005;23:303-310.
16. Li PK, Ariza A, Culleton BF, et al, IMPENDIA and EDEN Study Groups. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol. 2013;24:1889-1900.
17. Steinmetz J, Tarallo P, Fournier B, Caces E, Siest G. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur J Clin Chem Clin Biochem. 1995;33:337-342.
18. Tietz NW. Techniques and procedures to minimize laboratory infections. Specimen collection and storage recommendations. In: Tietz NW, editor. Textbook of Clinical Chemistry. Philadelphia, PA: WB Saunders Co, 1986. p. 478-497 52-53.
19. BN ProSpec System Assay Protocols (US). Manual Version 1.1, Siemens Healthcare Diagnostics, 2007.
20. N Apolipoprotein Standard Instructions for Use (IFU). 2008, Siemens Healthcare Diagnostics.
21. Gokal R, Moberly J, Lindholm B, Mujais S. Metabolic and laboratory effects of icodextrin. Kidney Int. 2002;62(Suppl 81):S62-S71.
22. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2009;32:2104-2112.
23. Barter PJ, Ballantyne CM, Carmena R, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259:247-258.
24. Cianflone K, Zhang Z, Vu H, Kohen-Avramoglu R, Kalant D, Sniderman AD. The effect of individual amino acids on ApoB100 and Lp(a) secretion by HepG2 cells. J Biol Chem. 1996;271:2936-2945.
25. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499-2506.
26. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between lowdensity lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5:105-113.
27. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham offspring study - implications for LDL management. J Clin Lipidol. 2007;1: 583-592.
28. Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the interheart study. Atherosclerosis. 2012;225:444-449.
29. Mora S, Buring JE, Ridker PM. Discordance of LDL cholesterol with alternative LDL-related measures and future coronary events [epub ahead of print]. Circulation. doi:10.1161/CIRCULATIONAHA.113. 005873, accessed 2013 Dec 17
30. NHANES Investigators. NHANES Analytic and Reporting Guidelines: 2003-2004. Available at: http://www.cdc.gov/nchs/data/nhanes/ nhanes-03-04/nhanes-analytic-guidelines-dec-2005.pdf. Accessed January 24, 2013.
31. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25:567-579.
32. Catapano AL, Reiner Z, De Backer G, et al, European Society of Cardiology (ESC), European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;21:3-46.